With the support of the major scientific and technological project of "Innovative Drugs and Modernization of Traditional Chinese Medicine", the oral recombinant intramolecular adjuvant vaccine for Helicobacter pylori developed by the Third Military Medical University made great progress, and was approved for phase III clinical research on June 5, 2004 and February 3, 2004. This vaccine is the only Helicobacter pylori vaccine that has entered the clinical research in China at present, and it is also the first Helicobacter pylori vaccine approved to enter the third phase of clinical research in the world, and it is expected to become the first Helicobacter pylori vaccine in the world.

In July 2002, the oral recombinant intramolecular adjuvant vaccine of Helicobacter pylori developed in China completed the preclinical research work of pharmacy, pharmacology, toxicology and pilot test. On May 9, 2003, 19, it was approved for phase I and II clinical research; In June, 2004, I and II clinical studies were completed. The results showed that the vaccine was safe and the immune response effect was remarkable. At present, the third phase of clinical research has been started, and it is estimated that the number of people participating in clinical trials will reach more than 1 10,000.

At present, combined antibiotics are mainly used to treat Hp infection, but there are some shortcomings, such as wide drug resistance, great toxic and side effects, easy recurrence, high medical expenses and inability to completely eliminate Hp. At present, the application of vaccine to prevent Helicobacter pylori infection is a hot spot in the international research of Helicobacter pylori prevention and control technology. Hp vaccine has dual functions of prevention and adjuvant therapy, and has broad market prospects.

A national first-class new drug, genetically engineered Helicobacter pylori vaccine (i.e. gastropathy vaccine) 0008 19.

Research project of hepatitis B therapeutic peptide, 600 132.

In the Third Military Medical University, it passed the final acceptance of the expert group. Professor Zou of the Third Military Medical University led the research team to adopt the molecular construction mode of genetic engineering vaccine, successfully established a long-term and stable animal infection model, overcame the destructive effect of gastric acid and pepsin on the vaccine, and improved the effectiveness and stability of Helicobacter pylori vaccine. Professor Wu led the research group to complete the screening, optimization and pilot test of hepatitis B vaccine, successfully completed all the work of intermediate test and pre-clinical evaluation, and obtained the approval of clinical research issued by the state. The vaccine is the world's first hepatitis B therapeutic vaccine, the first liposome freeze-dried drug in China and the first polypeptide vaccine in China.